Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 06, 2010 11:27 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Completes Public Offering of Common Stock

CHARLOTTE, N.C., Oct. 6, 2010 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) has completed its previously announced public offering of common stock and announced that the...
October 01, 2010 08:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Prices Public Offering of Common Stock

CHARLOTTE, N.C., Oct. 1, 2010 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced today that it has priced a public offering of approximately 7.14 million shares of...
September 28, 2010 16:00 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Announces Public Offering of Common Stock

CHARLOTTE, N.C., Sept. 28, 2010 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced today its intention, subject to market and other conditions, to offer $35 million...
September 27, 2010 07:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Initiates CH-4051 Phase II Trial in Rheumatoid Arthritis

CHARLOTTE, N.C., Sept. 27, 2010 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) has initiated enrollment in a multinational, 12-week, double-blind Phase II trial designed to...
September 20, 2010 06:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Reports Phase III Trial of Northera Met Primary Endpoint and Achieved Highly Significant Symptomatic Benefits in Neurogenic Orthostatic Hypotension

Northera Provided Statistically Significant Improvement Over Placebo on Composite Orthostatic Questionnaire Score (p=0.003) Study Showed Statistically Significant Benefits in all 3 Composite...
September 08, 2010 07:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics to Present at Rodman & Renshaw 12th Annual Healthcare Conference

CHARLOTTE, N.C., Sept. 8, 2010 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the Rodman & Renshaw 12th Annual Healthcare Conference at 11:40...
August 26, 2010 07:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Announces FDA Approval of CH-4051 Phase II Protocol

CHARLOTTE, N.C., Aug. 26, 2010 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced confirmation by the U.S. Food and Drug Administration (FDA) that its proposed Phase...
August 19, 2010 07:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Announces Initiation of Investigator-Led Phase II Study of Droxidopa in Chronic Fatigue Syndrome

CHARLOTTE, N.C., Aug. 19, 2010 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that a new investigator-led phase II clinical study of Droxidopa, an oral synthetic...
July 27, 2010 16:05 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Reports Second Quarter 2010 Results

Top-line Data from Pivotal Phase III Northera Study 301 in Neurogenic Orthostatic Hypotension Expected In September 2010 Full Enrollment of Northera Study 306 on Track for Completion by Year...
July 21, 2010 07:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics to Host Conference Call to Discuss Second Quarter 2010 Results

CHARLOTTE, N.C., July 21, 2010 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it will release second quarter results for the period ended June 30, 2010 after...